Navigation Links
Experimental agent briefly eases depression rapidly in test
Date:12/12/2012

A drug that works through the same brain mechanism as the fast-acting antidepressant ketamine briefly improved treatment-resistant patients' depression symptoms in minutes, with minimal untoward side effects, in a clinical trial conducted by the National Institutes of Health. The experimental agent, called AZD6765, acts through the brain's glutamate chemical messenger system.

Existing antidepressants available through prescription, which work through the brain's serotonin system, take a few weeks to work, imperiling severely depressed patients, who can be at high risk for suicide. Ketamine also works in hours, but its usefulness is limited by its potential for dissociative side-effects, including hallucinations. It is being studied mostly for clues to how it works.

"Our findings serve as a proof of concept that we can tap into an important component of the glutamate pathway to develop a new generation of safe, rapid-acting practical treatments for depression," said Carlos Zarate, M.D., of the NIH's National Institute of Mental Health, which conducted the research.

Zarate, and colleagues, reported on their results online Dec. 1, 2012 in the journal Biological Psychiatry.

AZD6765, like ketamine, works by blocking glutamate binding to a protein on the surface of neurons, called the NMDA receptor. It is a less powerful blocker of the NMDA receptor, which may be a reason why it is better tolerated than ketamine.

About 32 percent of 22 treatment-resistant depressed patients infused with ASD6765 showed a clinically meaningful antidepressant response at 80 minutes after infusion that lasted for about half an hour with residual antidepressant effects lasting two days for some. By contrast, 52 percent of patients receiving ketamine show a comparable response, with effects still detectable at seven days. So a single infusion of ketamine produces more robust and sustained improvement, but most patients continue to experience some symptoms with both drugs.

However, depression rating scores were significantly better among patients who received AZD6765 than in those who received placebos. The researchers deemed this noteworthy, since, on average, these patients had failed to improve in seven past antidepressant trials, and nearly half failed to respond to electroconvulsive therapy (ECT).

The patients reported only minor side effects, such as dizziness and nausea, which were not significantly different from those experienced with the placebo.

Zarate and colleagues say their results warrant further trials with AZD6765, testing whether repeated infusions a few times per week or higher doses might produce longer-lasting results.


'/>"/>

Contact: Jules Asher
NIMHpress@nih.gov
301-443-4536
NIH/National Institute of Mental Health
Source:Eurekalert

Related medicine news :

1. NIH-funded trial launched to assess experimental TB drug
2. Experimental graft-vs.-host disease treatment equivalent to standard care in Phase 3 trial
3. Experimental Antidepressant Appears Quick-Acting, Safe
4. More than a third of high-risk leukemia patients respond to an experimental new drug
5. Updated Clinical Results Show Experimental Agent Ibrutinib as Highly Active in CLL Patients
6. Experimental Insomnia Drug Shows Promise
7. Experimental Dengue Vaccine Shows Some Success
8. Standard chemotherapy provides higher survival rate than experimental in lung cancer patients
9. Cancer turns off important immune cells, complicating experimental vaccine therapies
10. Experimental Drug May Cut Severe Asthma Attacks: Study
11. Experimental Drug Suppresses Appetite in Mice: Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/23/2017)... ... 23, 2017 , ... MobilityWorks ®, the nation's largest ... 2017 Inc. 500|5000, an exclusive ranking of America’s fastest-growing private companies. MobilityWorks (aka ... marking the twelfth year that the company has been included on the list. ...
(Date:8/23/2017)... ... August 23, 2017 , ... The non-profit ... holding an inaugural State of the Science Symposium in partnership with the Global ... 2017. , This symposium provides a forum for global leaders in human nutrition ...
(Date:8/22/2017)... ... 2017 , ... Pivot Point Consulting, a ... the firm’s new Consulting Services Executive. Mr. Tisch will oversee all aspects of ... clients with initial vendor selection and pre-implementation planning through go-live support and post-live ...
(Date:8/22/2017)... ... August 22, 2017 , ... “To Walk Away”: a captivating and romantic ... Edward Koontz. “To Walk Away” is the creation of published author, Larry R. Sherman, ... hundred manuscripts in chemistry and religion, as well as four novels. , Though ...
(Date:8/22/2017)... (PRWEB) , ... August 22, 2017 , ... ... Mr. Stewart is the Founder and Managing Member for t4 Leadership Development & ... become critical to his definition of “success”: physician leadership development, servant leadership, data ...
Breaking Medicine News(10 mins):
(Date:8/17/2017)... , Aug. 17, 2017 MJAC2017 , ... – Canna Broadcast Media, today reveals its leading lineup. ... International Inc., a global cannabis innovator specializing in the development ... of the conference. MassRoots, Rambridge™ and The Green Organic Dutchman ... Inc. and Namaste Vapes™ as silver sponsors. ...
(Date:8/15/2017)... and Gulf Coast Regional Blood Center to host a blood ... Law family has had 3 members that needed blood products ... is partnering with Gulf Coast Regional Blood Center of ... supplies are running low. Gulf Coast Regional Blood Center,s inventory is ... is why the blood center reached out to Mostyn Law ...
(Date:8/15/2017)... AccuGenomics, Inc., a diagnostic company based in ... the company has provided an AccuKit to the HIV ... Chapel Hill and to Qura Therapeutics for evaluation in ... HIV reservoir and viral expression in human CD4+ T ... Center is a joint initiative between the University of ...
Breaking Medicine Technology: